Cited by 787Schizophrenia research and treatmentMental Health and PsychiatryBipolar Disorder and Treatment

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Neuroleptics and the Natural Course of Schizophrenia

Wyatt, R. J.·1991·Schizophrenia Bulletin

Open this paper in CoChat — free account

Abstract

To determine if neuroleptic treatment changes the natural course of schizophrenia, 22 studies were reviewed in which relatively similar patients were or were not given neuroleptics at specific times during the course of their illness. Nineteen of the studies were from first- or predominantly first-break populations. While there was little consensus among the authors of the studies reviewed, a reanalysis of the data indicates that early intervention with neuroleptics in first-break schizophrenic patients increases the likelihood of an improved long-term course. This finding is similar to that of earlier investigators who indicated there was a decrease in patients with the more severe forms of the illness following the introduction of convulsive therapies. Furthermore, there is evidence that stable schizophrenic patients whose neuroleptics are discontinued and have relapses may have a difficult time returning to their previous level of function. The findings describe in this paper have implications for both the treatment of schizophrenia and for understanding the pathophysiological processes that determine the course of the disorder.

Integrity signals

Registry

Crossref · 10.1093/schbul/17.2.325

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,907
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
International Classification of Diseases, 10th Revision
Tassé, M. J., & Bush, K. (2018) · Sage eBooks · doi:10.4135/9781483392271.n276 · Cited by 1,921
Drug and Family Therapy in the Aftercare of Acute Schizophrenics
Goldstein, M. J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340019001 · Cited by 521
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., Macmillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Schizophrenia, just the facts
Wyatt, R. J., Alexander, R., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 478
Self-citation
Neuropathology of Schizophrenia
Stevens, J. R. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290100011003 · Cited by 474
Longitudinal Studies of Schizophrenic Patients
Huber, G., Gross, G., Schüttler, R., Linz, M. H., & Clemens, S. L. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.4.592 · Cited by 439

Show all 73 references

Sorted by citations

Items 301–400 of 787

Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community
Thirthalli, J., Venkatesh, B. K., Naveen, M. N., Venkatasubramanian, G., Arunachala, U., Kumar, K. K., & Gangadhar, B. N. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.58893 · Cited by 38
Duration of untreated psychosis and pathways to psychiatric services in first‐episode schizophrenia
Yamazawa, R., Mizuno, M., Nemoto, T., Miura, Y., MURAKAMI, M., & Kashima, H. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01196.x · Cited by 39
Risks of Withdrawing Antipsychotic Medications
Wyatt, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150037007 · Cited by 38
Self-citation
Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine
de Castro, A. P. W., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300004 · Cited by 37
Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
ANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 37
Overview of severe mental illness
Johnson, D. L. (1997) · Clinical Psychology Review · doi:10.1016/s0272-7358(97)00017-2 · Cited by 37
Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits
Weiner, I., & Joel, D. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06765-9_13 · Cited by 37
Recent Advances in the Pharmacotherapy of Schizophrenia
Borison, R. L. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030552 · Cited by 36
A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia
Altamura, A. C. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90017-d · Cited by 36
The treatment of schizophrenia: Can we raise the standard of care?
Catts, S. V., & O’Toole, B. I. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416672725 · Cited by 35
Age-Related Reduction in Cortical Thickness in First-Episode Treatment-Naïve Patients with Schizophrenia
Lin, Y., Li, M., Zhou, Y., Deng, W., Ma, X., Wang, Q., Guo, W., Li, Y., Jiang, L., Hu, X., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00348-x · Cited by 34
The effect of motivational interviews on treatment adherence and insight levels of patients with schizophrenia: A randomized controlled study
Ertem, M., & Duman, Z. Ç. (2018) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12301 · Cited by 34
The Nature of Schizophrenia: Signposts to Prevention
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/000486700217 · Cited by 34
The Nature of Schizophrenia: Signposts to Prevention
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/000486740003401s03 · Cited by 34
Treating early psychosis: who, what, and when?
Cornblatt, B. A., & Auther, A. M. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.1/bcornblatt · Cited by 34
Research update: psychoeducational family interventions
Fadden, G. (1998) · Journal of Family Therapy · doi:10.1111/1467-6427.00088 · Cited by 52
Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics
Benmessaoud, D., Hamdani, N., Boni, C., Ramoz, N., Hamon, M., Kacha, F., & Gorwood, P. A. P. M. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-40 · Cited by 33
Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 33
Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics
Hitri, A., Casanova, M. F., Kleinman, J. E., Weinberger, D. R., & Wyatt, R. J. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00202-e · Cited by 33
Self-citation
Research and treatment strategies in first-episode psychoses: The Pittsburgh experience
Keshavan, M. S., Schooler, N. R., Sweeney, J. A., Haas, G. L., & Pettegrew, J. W. (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297675 · Cited by 33
Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia
Yu, M., Tan, Q., Wang, Y., Xu, Y., Wang, T., Liu, D., Chen, D., Deng, P., Huang, C., Liang, X., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1112657 · Cited by 32
Early intervention in schizophrenia: Current and future perspectives
Keshavan, M. S., & Amirsadri, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0040-8 · Cited by 32
Discovery and development of integrative biological markers for schizophrenia
Oertel‐Knöchel, V., Bittner, R. A., Knöchel, C., Prvulovic, D., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.006 · Cited by 33
Antipsychotic treatment effects and structural MRI brain changes in schizophrenia
Emsley, R. A., du Plessis, S. S., Phahladira, L., Luckhoff, H. K., Scheffler, F., Kilian, S., Smit, R., Buckle, C., Chiliza, B., & Asmal, L. (2021) · Psychological Medicine · doi:10.1017/s0033291721003809 · Cited by 31
Music and Psychosis
Backer, J. D. (2008) · Nordic Journal of Music Therapy · doi:10.1080/08098130809478202 · Cited by 37
An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis.
Malla, A., Chue, P., Jordan, G., Stip, E., Koczerginski, D., Milliken, H., Joseph, A., Williams, R., Adams, B., Manchanda, R., et al. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mach.061213 · Cited by 30
Schizophrenia: still Kraepelin's Dementia Praecox?
Häfner, H. (2004) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00003328 · Cited by 30
Early Intervention and Sustaining the Management of Vulnerability
Birchwood, M. J. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/000486700241 · Cited by 30
Duration of untreated psychosis and cognitive functioning
Rapp, C., Studerus, E., Bugra, H., Aston, J., Tamagni, C., Walter, A., Pflueger, M. O., Borgwardt, S., & Riecher‐Rössler, A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.12.016 · Cited by 30
Factors associated with non evidence-based prescribing of antipsychotics
Connolly, A., & Taylor, D. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540298 · Cited by 30
A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia
Stip, É., Vincent, P. D., Sablier, J., Guevremont, C., Zhornitsky, S., & Tranulis, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00100 · Cited by 30
Treatment resistant schizophrenia: Course of brain structure and function
Harvey, P. D., & Rosenthal, J. B. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.008 · Cited by 30
Duration of untreated psychosis: An important target for intervention in schizophrenia?
Johannessen, T. K. L. J. O. (1999) · Nordic Journal of Psychiatry · doi:10.1080/080394899427089 · Cited by 30
Introduction to ‘Early psychosis: abridge to the future’
McGorry, P. D., Nordentoft, M., & Simonsen, E. H. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.48.s1 · Cited by 30
Impact of duration of untreated psychosis and premorbid intelligence on cognitive functioning in patients with first-episode schizophrenia
Wang, M., Ho, N. F., Sum, M. Y., Collinson, S. L., & Sim, K. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.002 · Cited by 29
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
Pillai, A., Schooler, N. R., Peter, D., Looney, S. W., GOFF, D. C., Kopelowicz, A. J., Lauriello, J., Manschreck, T. C., Mendelowitz, A. J., Miller, D. D., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.06.059 · Cited by 31
The role of ethnicity in treatment refractory schizophrenia
Teo, C., Borlido, C., Kennedy, J. L., & Luca, V. D. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.07.002 · Cited by 29
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis
Crespo‐Facorro, B., Pérez‐Iglesias, R., Mata, I. F., Martínez‐García, O., de la Foz, V. O., Pelayo‐Terán, J. M., Valdizán, E. M., & Vázquez‐Barquero, J. L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2392-3 · Cited by 29
Treatment of patients with first-episode psychosis: two-year outcome data from the Danish National Schizophrenia Project.
Rosenbaum, B., Valbak, K., Harder, S. K., Knudsen, P. B., Køster, A., Lajer, M., Lindhardt, A., Winther, G., Petersen, L., Jørgensen, P., et al. (2006) · PubMed · Cited by 29
The long-term effects of placebo in patients with chronic schizophrenia
Wyatt, R. J., Henter, I. D., & Bartko, J. J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00227-9 · Cited by 29
Self-citation
Prevalence and Incidence of Schizophrenia Spectrum Disorders: Implications for Prevention
Jablensky, A. V. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/000486740003401s05 · Cited by 29
Computed tomography of the brain morphology of patients with first-episode schizophrenic psychosis
MALLA, A. K., Mittal, C., Lee, M., Scholten, D. J., Assis, L. J. P., & Norman, R. M. G. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0253 · Cited by 29
Placebo-controlled studies in schizophrenia—ethical and scientific perspectives: an overview of conference proceedings
Zipursky, R. B., & Darby, P. L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00124-8 · Cited by 29
Biobehavioral treatment and rehabilitation of schizophrenia
Liberman, R. P., Kopelowicz, A. J., & Young, A. S. (1994) · Behavior Therapy · doi:10.1016/s0005-7894(05)80147-9 · Cited by 29
Early Intervention for Schizophrenic Disorders: Implementing Optimal Treatment Strategies in Clinical Services
Gråwe, R. W., Widen, J. H., & Falloon, I. R. H. (2002) · Springer eBooks · doi:10.1007/978-4-431-68514-2_31 · Cited by 29
A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia
(2002) · New England Journal of Medicine · doi:10.1056/nejm200205023461826 · Cited by 29
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
Fountoulakis, K. Ν., Moeller, H.-J., Kasper, S. F., Tamminga, C. A., Yamawaki, S., Kahn, R. S., Tandon, R., Correll, C. U., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 28
Ethical problems in psychiatric research
Lehrman, N. S., & Sharav, V. H. (1997) · The Journal of Behavioral Health Services & Research · doi:10.1007/bf02898516 · Cited by 28
Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington, G. J., & Chong, S. A. (1999) · PubMed Central · Cited by 28
Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up
Ohmori, T., Ito, K., Abekawa, T., & Koyama, T. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050069 · Cited by 28
Anatomy of Schizophrenia Revisited
Stevens, J. R. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.3.373 · Cited by 29
Rehab Rounds : Psychosocial Rehabilitation Early After the Onset of Psychosis
Whitehorn, D., Lazier, L., & Kopala, L. C. (1998) · Psychiatric Services · doi:10.1176/ps.49.9.1135 · Cited by 28
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration
Kim, S., Kim, S., Koh, M., Choi, G., Kim, J.-J., Paik, I., Kim, S., Choi, Y. S., Lee, Y. H., Suh, J., et al. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13446 · Cited by 27
Religious Beliefs and Their Relevance for Treatment Adherence in Mental Illness: A Review
Zagożdżon, P., & Wrotkowska, M. (2017) · Religions · doi:10.3390/rel8080150 · Cited by 27
Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial
Chung, Y., Lee, C.-R., Park, T.-W., Yang, K.-H., & Kim, K. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701432551 · Cited by 27
Follow-up studies of schizophrenia I: Natural history and non-psychopathological predictors of outcome
van Os, J., Wright, P., & Murray, R. M. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83576-6 · Cited by 27
Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions
Yarlagadda, A. (2002) · Medical Hypotheses · doi:10.1054/mehy.2001.1511 · Cited by 27
Early intervention in psychotic disorders: Challenges and relevance in the Indian context
Keshavan, M., Shrivastava, A., & Gangadhar, B. N. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69228 · Cited by 27
Emergency Psychiatry: Extrapyramidal Side Effects in the Psychiatric Emergency Service
Kamin, J., Manwani, S. G., & Hughes, D. H. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.3.287 · Cited by 27
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden
Jørgensen, K. T., Bøg, M., Kabra, M., Simonsen, J., Adair, M., & Jönsson, L. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03634-z · Cited by 28
The rationale for early intervention in schizophrenia and related disorders
Nordentoft, M., Jeppesen, P., Petersen, L., Bertelsen, M., & Thorup, A. A. E. (2009) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2009.00123.x · Cited by 26
Early premorbid adjustment as a moderator of the impact of duration of untreated psychosis
Norman, R. M. G., MALLA, A. K., & Manchanda, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.007 · Cited by 26
Examining the effectiveness of antipsychotic medication in first-episode psychosis
Taylor, M., Cavanagh, J., Hodgson, R. E., & Tiihonen, J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439252 · Cited by 25
Evaluating the importance of reducing the duration of untreated psychosis
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00782.x · Cited by 26
Including Children and Adolescents With Schizophrenia in Medication-Free Research
Kumra, S., Briguglio, C., Lenane, M., Goldhar, L., Bedwell, J. S., Venuchekov, J., Jacobsen, L. K., & Rapoport, J. L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1065 · Cited by 26
Electroconvulsive Therapy and Schizophrenia
Sackeïm, H. A. (2003) · doi:10.1002/9780470987353.ch27 · Cited by 26
Duration of active psychosis and functional outcomes in first-episode non-affective psychosis
Pelayo‐Terán, J. M., Gajardo-Galán, V., Gómez‐Revuelta, M., de la Foz, V. O., Ayesa‐Arriola, R., Tabarés‐Seisdedos, R., & Crespo‐Facorro, B. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.03.003 · Cited by 25
The neurobiology of duration of untreated psychosis: a comprehensive review
Zoghbi, A. W., Lieberman, J. A., & Girgis, R. R. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01718-0 · Cited by 27
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine
Crespo‐Facorro, B., Pérez‐Iglesias, R., Mata, I. F., Caseiro, O., Martínez‐García, O., Pardo‐García, G., Ramírez-Bonilla, M., Pelayo‐Terán, J. M., & Vázquez‐Barquero, J. L. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.11.002 · Cited by 25
Prevention and Recovery in Early Psychosis (PREP®): Building a public-academic partnership program in Massachusetts, United States
Caplan, B., Zimmet, S. V., Meyer, E. C., Friedman‐Yakoobian, M. S., Monteleone, T., Leung, Y. J., Guyer, M. E., Rood, L. L., Keshavan, M. S., & Seidman, L. J. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.10.009 · Cited by 25
Recovery from schizophrenia: A criterion-based definition.
Liberman, R. P., & Kopelowicz, A. J. (2005) · American Psychological Association eBooks · doi:10.1037/10848-005 · Cited by 26
Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View
Leung, C. C.-Y., Gadelrab, R., Ntephe, C., McGuire, P. K., & Demjaha, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00601 · Cited by 26
Systematic comparison of duration of untreated illness versus duration of untreated psychosis in relation to psychopathology and dysfunction in the Cavan-Monaghan first episode psychosis study (CAMFEPS)
Nkire, N., Scully, P. J., Browne, D. J., Baldwin, P. A., Kingston, T., Owoeye, O., Kinsella, A., O’Callaghan, E., Russell, V., & Waddington, J. L. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.03.003 · Cited by 25
EMERGING ROLES FOR NOVEL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA
Andersson, C., Chakos, M., Mailman, R. B., & Lieberman, J. A. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70365-8 · Cited by 25
Treatment‐Resistant Schizophrenia
Barnes, T. R. E., Buckley, P. F., & Schulz, S. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch26 · Cited by 25
10 year course of IQ in first-episode psychosis: Relationship between duration of psychosis and long-term intellectual trajectories
Barder, H. E., Sundet, K. S., Rund, B. R., Evensen, J. H., Haahr, U., Hegelstad, W. T. V., Joa, I., Johannessen, J. O., Langeveld, J., Larsen, T. K., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.054 · Cited by 24
Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study
de Santayana, G. P., Vázquez-Bourgón, J., Gómez‐Revuelta, M., Ayesa‐Arriola, R., de la Foz, V. O., Crespo‐Facorro, B., & Pelayo‐Terán, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.009 · Cited by 24
When Should Clozapine Be Initiated in Schizophrenia?
Kerwin, R. W. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00002 · Cited by 24
Relationship of good and poor Wisconsin Card Sorting Test performance to illness duration in schizophrenia: a cross-sectional analysis
Stratta, P., Arduini, L., Daneluzzo, E., Rinaldi, O., Genova, A. D., & Rossi, A. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00256-7 · Cited by 24
CHILD AND ADOLESCENT SCHIZOPHRENIA
Schulz, S. C., Findling, R. L., Wise, A. L., Friedman, L., & Kenny, J. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70360-9 · Cited by 24
Managing the first episode of schizophrenia: the role of new therapies
McCreadie, R. G. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00013-2 · Cited by 24
Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
Sharif, Z. A. (2008) · Patient Preference and Adherence · doi:10.2147/ppa.s3346 · Cited by 25
The quality of life in patients with schizophrenia in community mental health service - selected factors
Makara‐Studzińska, M., Wołyniak, M., & Partyka, I. (2011) · Jagiellonian University Repository (Jagiellonian University) · Cited by 23
The Temporal Relationship Between Symptom Change and Treatment Discontinuation in a Pooled Analysis of 4 Schizophrenia Trials
Kinon, B. J., Ascher‐Svanum, H., Adams, D. H., & Chen, L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e74a · Cited by 23
Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol
de Sena, E. P., Santos‐Jesus, R., Miranda‐Scippa, Â., Quarantini, L. D. C., & de Oliveira, I. R. (2003) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462003000400007 · Cited by 23
Practical Geriatrics: Directions for Research and Policy on Schizophrenia and Older Adults: Summary of the GAP Committee Report
Cohen, C. I. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.3.299 · Cited by 23
EEG abnormalities and two year outcome in first episode psychosis
Manchanda, R., Norman, R. M. G., MALLA, A. K., Harricharan, R., Takhar, J., & Northcott, S. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00490.x · Cited by 23
Age Disorientation in Schizophrenia
Manschreck, T. C., Maher, B. A., Winzig, L., Candela, S. F., Beaudette, S., & Boshes, R. A. (2000) · Journal of Neuropsychiatry · doi:10.1176/jnp.12.3.350 · Cited by 23
Fortnightly review: Treatment of schizophrenia
McGrath, J. J., & Emmerson, B. (1999) · BMJ · doi:10.1136/bmj.319.7216.1045 · Cited by 23
Neurostructural changes in schizophrenia and treatment-resistance: a narrative review
Paul, T., See, J. W., Vijayakumar, V., Njideaka-Kevin, T., Loh, H., Lee, V. J. Q., & Doğrul, B. N. (2024) · Psychoradiology · doi:10.1093/psyrad/kkae015 · Cited by 23
Does a four-week delay in the introduction of medication alter the course of functional psychosis?
Johnstone, E. C., Owens, D. G. C., Crow, T. J., & Davis, J. M. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300305 · Cited by 22
Predictors of response in a sample of treatment-resistant psychotic patients on clozapine
Ciapparelli, A., Ducci, F., Carmassi, C., Carlini, M., Paggini, R., Catena, M., Bottai, M., & Dell’Osso, L. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0511-4 · Cited by 22
Antipsychotic Maintenance Treatment of Schizophrenia Patients: Is There a Consensus?
Meise, U., Kurz, M., & Fleischhacker, W. W. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.1.215 · Cited by 22
Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials
Levine, S. Z., & Leucht, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.005 · Cited by 20
Effect of time and duration of untreated psychosis on cognitive and social functioning in Chinese patients with first-episode schizophrenia: A 1-year study
Heeramun‐Aubeeluck, A., Liu, N., Fischer, F. H., Huang, N., Chen, F., He, L., Yang, C., Luo, Y., & Lu, Z. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2014.929738 · Cited by 21
Risperidone in acute and long-term therapy of schizophrenia—a clinical profile
Pajonk, F. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00164-7 · Cited by 21
A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway
Pinault, D. (2017) · Brain Sciences · doi:10.3390/brainsci7040034 · Cited by 23
Neurodevelopmental impairment, dopamine sensitisation, and social adversity in schizophrenia.
Murray, R. M., McDonald, C., & Bramon, E. (2002) · PubMed · Cited by 21
First-episode schizophrenia: Do grandiosity, disorganization, and acute initial development reduce duration of untreated psychosis? An exploratory naturalistic case study
Møller, P. (2000) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(00)90046-4 · Cited by 22
Review of Antipsychotic Medication Administration: A Proposal of Intermittent Dosing
Boshes, R. A., & Manschreck, T. C. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006932 · Cited by 21

Authors: Wyatt, R. J.
Affiliations: St. Elizabeths Hospital (US)
Corresponding author: Wyatt, R. J.
Venue: Schizophrenia Bulletin
Publisher: Oxford University Press (OUP)
Published: 1991-01-01
Volume: 17
Issue: 2
Pages: 325-351
ISSN: 0586-7614 (ISSN-L)
1745-1701
DOI: 10.1093/schbul/17.2.325
OpenAlex: W2120012268
Cited by: 787
References: 73
Citations by year: 2026: 6 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 21 · 2020: 12 · 2019: 48 · 2018: 14 · 2017: 18 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 22 · 2012: 27
FWCI: 13.18
Type: journal article
Language: en
Open access: closed
Locations: Schizophrenia Bulletin (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic drugs
MeSH terms: Humans, Recurrence, Schizophrenia, Time Factors, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuroleptics and the Natural Course of Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks